Research and professional experience :

1. Personal Statement

PharmD by background, he completed a MSc and a PhD in health biology and medical sciences, respectively. As a Medical Scientist, specialized in epidemiology and clinical research, he actively contributes to the design and implementation of research projects, including epidemiological studies and clinical trials on malaria and other infectious diseases. As ISO certified auditor for quality management systems, he has an oversight of the quality management system of the CRUN at the position of deputy head and QA manager. More than fifteen years’ experience in clinical research with a track record of more than 30 projects successfully implemented. Lecturer and consultant in monitoring/evaluation of health interventions and particularly malaria control programs. Actively involved in several health sciences research projects covering capacity building, community based interventions and product development. Specific interest on epidemiology, drugs and vaccines development for the control of infectious diseases and community based interventions to reduce child mortality. Strong expertise in implementing international research standards. Good skills and experience in networking and team building. Ten-year’s experience as deputy head of the Clinical Research Unit of Nanoro, Burkina Faso and two-year’s experience as Executive director of the National Centre for Research and Training on Malaria, Ministry of Health, Burkina Faso. Consultant for the World Health Organisation country office in Burkina Faso and associate lecturer of clinical research at University level.

2. Positions and Employment :

Since 2008 : Deputy Head/Quality assurance manager, Clinical Research Unit of Nanoro (IRSS/CRUN), Burkina Faso

2016 – 2018. Executive Director, National Centre for Research and Training on Malaria (CNRFP), Ministry of Health, Burkina Faso,

2008 – 2016 : Associate researcher, Department of Clinical Research, Centre Muraz, Bobo-Dioulasso-Burkina Faso,

2005 – 2007 : Network Manager, West African Network 2 for monitoring antimalarial treatments (WANMAT2), Bobo-Dioulasso – Burkina Faso,

2003 – 2005 : Pharmacist/Study monitor, Vaccinology and Epidemiology unit, Centre Muraz, Bobo-Dioulasso – Burkina Faso,

Other Experience and Professional Memberships :

Partnership for Increasing the Impact of Vector Control (PIIVeC)

Société Burkinabé de Biologie Clinique

African Society for Laboratory Medicine (ASLM)

European Society for Medical Decision Making, (SMDM)

American Society for Tropical Medicine and Hygiene (ASTMH)

3. Selected Peer-reviewed Publication

1: Skrip L, Derra K, Kaboré M, Noori N, Gansané A, Valéa I, Tinto H, Brice BW, Van Gordon M, Hagedorn B, Hien H, Althouse BM, Wenger EA, Ouédraogo AL. Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis. Int J Infect Dis. 2020 Sep 25:S1201-9712(20)32148-2. doi: 10.1016/j.ijid.2020.09.1432. Epub ahead of print. PMID: 32987177; PMCID: PMC7518969.

2: Bihoun B, Zango SH, Traoré-Coulibaly M, Valea I, Ravinetto R, Van Geertruyden JP, D’Alessandro U, Tinto H, Robert A. Fetal biometry assessment with Intergrowth 21st’s and Salomon’s equations in rural Burkina Faso. BMC Pregnancy Childbirth. 2020 Aug 26;20(1):492. doi: 10.1186/s12884-020-03183-5. PMID: 32847549; PMCID: PMC7449020.

3: Sondo P, Derra K, Rouamba T, Nakanabo Diallo S, Taconet P, Kazienga A, Ilboudo H, Tahita MC, Valéa I, Sorgho H, Lefèvre T, Tinto H. Determinants of Plasmodium falciparum multiplicity of infection and genetic diversity in Burkina Faso. Parasit Vectors. 2020 Aug 20;13(1):427. doi: 10.1186/s13071-020-04302-z. PMID: 32819420; PMCID: PMC7441709.

4: Rouamba T, Sondo P, Derra K, Nakanabo-Diallo S, Bihoun B, Rouamba E, Tarnagda Z, Kazienga A, Valea I, Sorgho H, Pagnoni F, Samadoulougou-Kirakoya F, Tinto H. Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso. Drug Des Devel Ther. 2020 Apr 16;14:1507-1521. doi: 10.2147/DDDT.S224857. PMID: 32368010; PMCID: PMC7174163.

5: Birgersson S, Valea I, Tinto H, Traore-Coulibaly M, Toe LC, Hoglund RM, Van Geertruyden JP, Ward SA, D’Alessandro U, Abelö A, Tarning J. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Res. 2019 Mar 7;4:45. doi: 10.12688/wellcomeopenres.14849.2. PMID: 32025570; PMCID: PMC6974929.

6: Valéa I, Adjei S, Usuf E, Traore O, Ansong D, Tinto H, Owusu Boateng H, Some AM, Buabeng P, Vekemans J, Kotey A, Vandoolaeghe P, Cullinane M, Traskine M, Ouedraogo F, Sambian D, Lievens M, Tahita MC, Jongert E, Lompo P, Idriss A, Borys D, Ouedraogo S, Prempeh F, Schuerman L, Sorgho H, Agbenyega T. Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine in African children: a randomized trial. Hum Vaccin Immunother. 2020 Jun 2;16(6):1464-1470. doi: 10.1080/21645515.2019.1695457. Epub 2020 Jan 17. PMID: 31951771; PMCID:PMC7482624.

7: Lingani M, Bonkian LN, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo JB, Mens PF, Schallig HDFH, Ravinetto R, d’Alessandro U, Tinto H. In vivo/exvivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malar J. 2020 Jan 6;19(1):8. doi:10.1186/s12936-019-3089-z. PMID: 31906948; PMCID: PMC6945612.

8: Tinto H, Otieno W, Gesase S, Sorgho H, Otieno L, Liheluka E, Valéa I, Sing’oei V, Malabeja A, Valia D, Wangwe A, Gvozdenovic E, Guerra Mendoza Y, Jongert E, Lievens M, Roman F, Schuerman L, Lusingu J. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infect Dis. 2019 Aug;19(8):821-832. doi: 10.1016/S1473-3099(19)30300-7. Epub 2019 Jul 9. PMID: 31300331.

9: Nambozi M, Tinto H, Mwapasa V, Tagbor H, Kabuya JB, Hachizovu S, Traoré M, Valea I, Tahita MC, Ampofo G, Buyze J, Ravinetto R, Arango D, Thriemer K, Mulenga M, van Geertruyden JP, D’Alessandro U. Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study. Malar J. 2019 Mar 28;18(1):105. doi: 10.1186/s12936-019-2737-7. PMID: 30922317; PMCID: PMC6437904.

10: Unger H, Thriemer K, Ley B, Tinto H, Traoré M, Valea I, Tagbor H, Antwi G, Gbekor P, Nambozi M, Kabuya JB, Mulenga M, Mwapasa V, Chapotera G, Madanitsa M, Rulisa S, de Crop M, Claeys Y, Ravinetto R, D’Alessandro U. The assessment of gestational age: a comparison of different methods from a malaria pregnancy cohort in sub-Saharan Africa. BMC Pregnancy Childbirth. 2019 Jan 8;19(1):12. doi: 10.1186/s12884-018-2128-z. PMID: 30621604; PMCID: PMC6323786.

11: Rouamba T, Valea I, Bognini JD, Kpoda H, Mens PF, Gomes MF, Tinto H, Kirakoya-Samadoulougou F. Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study. Drugs Real World Outcomes. 2018 Sep;5(3):193-206. doi: 10.1007/s40801-018-0141-1. PMID: 30155832; PMCID: PMC6119166.

12: Bonkian LN, Yerbanga RS, Koama B, Soma A, Cisse M, Valea I, Tinto H, Ouedraogo JB, Guigemde TR, Traore/Coulibaly M. In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice. Evid Based Complement Alternat Med. 2018 May 24;2018:6859632. doi: 10.1155/2018/6859632. PMID: 29977316; PMCID: PMC5994278.

13: Valéa I, Adjei S, Usuf E, Traore O, Ansong D, Tinto H, Owusu Boateng H, Leach A, Mwinessobaonfou Some A, Buabeng P, Vekemans J, Nana LA, Kotey A, Vandoolaeghe P, Ouedraogo F, Sambian D, Lievens M, Tahita MC, Rettig T, Jongert E, Lompo P, Idriss A, Borys D, Ouedraogo S, Prempeh F, Habib MA, Schuerman L, Sorgho H, Agbenyega T. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Hum Vaccin Immunother. 2018 Jun 3;14(6):1489-1500. doi:10.1080/21645515.2018.1442996. Epub 2018 Apr 13. PMID: 29630438; PMCID:PMC6037440.

14: Cates JE, Unger HW, Briand V, Fievet N, Valea I, Tinto H, D’Alessandro U, Landis SH, Adu-Afarwuah S, Dewey KG, Ter Kuile FO, Desai M, Dellicour S, Ouma P, Gutman J, Oneko M, Slutsker L, Terlouw DJ, Kariuki S, Ayisi J, Madanitsa M, Mwapasa V, Ashorn P, Maleta K, Mueller I, Stanisic D, Schmiegelow C, Lusingu JPA, van Eijk AM, Bauserman M, Adair L, Cole SR, Westreich D, Meshnick S, Rogerson S. Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Med. 2017 Aug 8;14(8):e1002373. doi: 10.1371/journal.pmed.1002373. PMID: 28792500; PMCID: PMC5549702.

15: Unger HW, Cates JE, Gutman J, Briand V, Fievet N, Valea I, Tinto H, d’Alessandro U, Landis SH, Adu-Afarwuah S, Dewey KG, Ter Kuile F, Dellicour S, Ouma P, Slutsker L, Terlouw DJ, Kariuki S, Ayisi J, Nahlen B, Desai M, Madanitsa M, Kalilani-Phiri L, Ashorn P, Maleta K, Mueller I, Stanisic D, Schmiegelow C, Lusingu J, Westreich D, van Eijk AM, Meshnick S, Rogerson S. Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. BMJ Open. 2016 Dec 21;6(12):e012697. doi:10.1136/bmjopen-2016-012697. PMID: 28003287; PMCID: PMC5223676.

17: Tinto H, Valea I, Ouédraogo JB, Guiguemdé TR. Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Ann Parasitol. 2016;62(1):17-24. doi: 10.17420/ap6201.27. PMID: 27262953.

18: Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, Van Overmeir C, Rosanas-Urgell A, Van Geertruyden JP, D’Alessandro U, Erhart A. In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso. AntimicrobAgents Chemother. 2015 Jan;59(1):734-7. doi: 10.1128/AAC.03647-14. Epub 2014 Nov17. PMID: 25403659; PMCID: PMC4291431.

19: Valea I, Tinto H, Traore-Coulibaly M, Toe LC, Lindegardh N, Tarning J, VanGeertruyden JP, D’Alessandro U, Davies GR, Ward SA. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. J Antimicrob Chemother. 2014 Sep;69(9):2499-507. doi: 10.1093/jac/dku154. Epub 2014 Jun 2. PMID: 24891429; PMCID: PMC4130382.

20: Tinto H, Valea I, Sorgho H, Tahita MC, Traore M, Bihoun B, Guiraud I, Kpoda H, Rouamba J, Ouédraogo S, Lompo P, Yara S, Kabore W, Ouédraogo JB, Guiguemdé RT, Binka FN, Ogutu B. The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malar J. 2014 Mar 22;13:113. doi: 10.1186/1475-2875-13-113. PMID: 24655351; PMCID: PMC3994337.

4. Research Support

ARES, Belgium: 2017 – 2021 : Amélioration de la santé maternelle et infantile par la prévention des co-infections paludisme et maladies sexuellement transmises chez les femmes enceintes au Burkina Faso (ARES), Principal Investigator

Dalhousie University, Canada : 2016 – 2021 : A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents (ACHIV-Ebola), Principal Investigator

GSK Biologicals, Belgium : 2011 – 2017 : Malaria 63 Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination with rotavirus vaccine and pneumococcal conjugate vaccine at 6, 10 and 14 weeks of age, to infants living in a malaria-endemic region in Africa, Principal investigator